

## Clinical Criteria

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

**Subject:** Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)

Formatted: Underline

**Document #:** JNG-CC-0169 **Publish Date:** 09/01/2020

Formatted: Font: Bold, Underline

**Status:** New **Last Review Date:** 08/21/2020

Formatted: Underline

Formatted: Font: Bold, Underline

### Table of Contents

Formatted: Underline

[Overview](#) [Coding](#) [References](#)

Formatted: Font: Bold, Underline

[Clinical criteria](#) [Document history](#)

Formatted: Font: Bold, Underline

Formatted: Underline

### Overview

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

This document addresses the use of Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf). Phesgo is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for the following FDA approved indications:

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

#### Early Breast Cancer (EBC)

For use in combination with chemotherapy for:

Formatted: Underline

- the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer
- the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

#### Metastatic Breast Cancer (MBC)

For use in combination with docetaxel for the treatment of adult patients

Formatted: Font: Bold, Underline

- with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease

Formatted: Underline

Formatted: Font: Bold, Underline

Phesgo is for subcutaneous use only in the thigh. It should not be administered intravenously. Also Phesgo has different dosage and administration instructions than intravenous pertuzumab, intravenous trastuzumab, and subcutaneous trastuzumab when administered alone. Phesgo cannot be substituted for or with pertuzumab, trastuzumab, ado-trastuzumab emtansine (Kadcyla), or fam-trastuzumab deruxtecan (Enhertu). Phesgo must always be administered by a healthcare professional.

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

The recommended initial dose of Phesgo is 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase administered SC over approximately 8 minutes, followed every 3 weeks by a dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase administered SC over approximately 5 minutes.

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

- In the neoadjuvant treatment setting, Phesgo should be administered for 3 to 6 cycles as part of a treatment regimen for early breast cancer. Following surgery, patients should continue to receive Phesgo to complete 1 year of treatment (up to 18 cycles) or until disease recurrence or unmanageable toxicity, whichever occurs first, as a part of a complete regimen for early breast cancer.
- In the adjuvant treatment setting, Phesgo should be administered for a total of 1 year (up to 18 cycles) or until disease recurrence or unmanageable toxicity, whichever occurs first, as part of a complete regimen for early breast cancer, including standard anthracycline- and/or taxane-based chemotherapy. Phesgo should be started on day 1 of the first taxane containing cycle.
- In the metastatic setting, Phesgo should be administered until disease progression or unmanageable toxicity, whichever occurs first.

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

#### Black Box Warning

Phesgo has black box warnings for cardiomyopathy, embryo-fetal toxicity, and pulmonary toxicity. Phesgo administration can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue Phesgo

for cardiomyopathy. Exposure to Phesgo can result in embryo-fetal death and birth defects. Discontinue Phesgo for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.

## Definitions and Measures

HER2 testing (adapted from American Society of Clinical Oncology/College of American Pathologists):

### Positive HER2:

- IHC 3+ based on circumferential membrane staining that is complete, intense. (Observed in a homogeneous and contiguous population and within > 10% of the invasive tumor cells).
- ISH positive based on:
  - Single-probe average HER2 copy number  $\geq 6.0$  signals/cell\*
  - Dual-probe HER2/CEP 17 ratio  $\geq 2.0^*$  with an average HER2 copy number  $\geq 4.0$  signals/cell
  - Dual-probe HER2/CEP17 ratio  $\geq 2.0^*$  with an average HER2 copy number  $< 4.0$  signals/cell
  - Dual-probe HER2/CEP17 ratio  $< 2.0^*$  with an average HER2 copy number  $\geq 6.0$  signals/cell

\*(Observed in a homogeneous and contiguous population and within >10% of the invasive tumor cells. By counting at least 20 cells within the area)

### Equivocal HER2:

- IHC 2+ based on circumferential membrane staining that is incomplete and/or weak/moderate and within >10% of the invasive tumor cells or complete and circumferential membrane staining that is intense and within  $\leq 10\%$  of the invasive tumor cells.
- ISH equivocal based on:
  - Single-probe average HER2 copy number  $\geq 4.0$  and  $< 6.0$  signals/cell
  - Dual-probe HER2/CEP17 ratio  $< 2.0$  with an average HER2 copy number  $\geq 4.0$  signals/cell

### Negative HER2 if a single test (or both tests) performed show:

- IHC 1+ as defined by incomplete membrane staining that is faint/barely perceptible and within > 10% of the invasive tumor cells
- IHC 0 as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within  $\leq 10\%$  of the invasive tumor cells
- ISH negative based on:
  - Single-probe average HER2 copy number  $< 4.0$  signals/cell
  - Dual-probe HER2/CEP17 ratio  $< 2.0$  with an average HER2 copy number  $< 4.0$  signals/cell

**Metastasis:** The spread of cancer from one part of the body to another; a metastatic tumor contains cells that are like those in the original (primary) tumor and have spread.

**Monoclonal antibody:** A protein developed in the laboratory that can locate and bind to specific substances in the body and on the surface of cancer cells.

**Targeted biologic agent:** A newer type of drug developed specifically to target genetic changes in cells that cause cancer. It works differently than standard chemotherapy drugs, often with different side effects.

## Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

### Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)

Requests for Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) may be approved if the following criteria are met:

- Individual has a diagnosis of HER2-positive (HER2+) breast cancer (NCCN 1) confirmed by one of the following:
  - Immunohistochemistry (IHC) is 3 +; OR
  - In situ hybridization (ISH) positive;

### AND

- One of the following:
  - Individual is using as neoadjuvant treatment; AND
  - Individual is using in combination with chemotherapy; AND
  - Individual has a diagnosis of locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer;

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

OR

- D. Individual is using as adjuvant treatment; AND  
E. Individual has a diagnosis of early breast cancer at high risk of recurrence;

OR

- F. Individual has a diagnosis of metastatic breast cancer; AND  
G. Individual has not received prior anti-HER2 therapy or chemotherapy for metastatic disease; AND  
H. Individual is using Phesgo in combination with docetaxel.

Requests for Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) may not be approved for the following:

- I. For all other indications not listed above; OR  
II. If used as a substitute for or with pertuzumab, trastuzumab, ado-trastuzumab emtansine (Kadcyla), or fam-trastuzumab deruxtecan (Enhertu) as a single agent.

## Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

### HCPCS

J3490	Unclassified drugs (when specified as pertuzumab, trastuzumab, and hyaluronidase-zzxf) (Phesgo)
J3590	Unclassified biologics (when specified as pertuzumab, trastuzumab, and hyaluronidase-zzxf) (Phesgo)
J9999	Not otherwise classified, antineoplastic drugs (when specified as pertuzumab, trastuzumab, and hyaluronidase-zzxf) (Phesgo)
C9399	Unclassified drugs or biologicals (when specified as pertuzumab, trastuzumab, and hyaluronidase-zzxf) (Phesgo) (HOSPITAL-OUTPATIENT-ONLY)

### ICD-10 Diagnosis

All diagnosis

## Document History

New: 08/21/2020

Document History:

- 08/21/2020– Annual Review: New criteria document for Phesgo. Coding Reviewed: Added ICD-10-CM: All dx pend, HCPCS J3490, J3590, J999, C9399

## References

- Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
- DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 20, 2020.
- DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
- Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
- NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on July 20, 2020.
  - Breast Cancer. V5.2020. Revised July 15, 2020.
- Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection for subcutaneous use. [Package Insert]. South San Francisco, CA. Genentech; June, 2020.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

Formatted: Font: Bold, Underline

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association